sarscov
believ
zoonot
origin
cross
human
like
unidentifi
anim
host
wild
game
market
guangdong
china
mani
first
infect
individu
novemb
decemb
contact
livegam
trade
diseas
first
call
infecti
atyp
pneumonia
caus
cluster
diseas
famili
health
care
worker
etiolog
agent
sar
identifi
new
cov
peiri
univers
hong
kong
viral
genom
fulli
sequenc
record
time
week
research
univers
british
columbia
center
diseas
control
genom
analysi
reveal
sarscov
new
cov
previous
found
human
absenc
antibodi
healthi
human
suggest
sarscov
recent
emerg
human
popul
anim
human
interspeci
transmiss
seem
probabl
explan
emerg
specimen
collect
appar
healthi
anim
wildgam
anim
market
china
indic
number
anim
includ
himalayan
palm
civet
cat
raccoon
dog
yield
sarscovlik
viru
nucleotid
homolog
human
mani
anim
handler
previou
histori
sarslik
ill
later
found
serum
antibodi
sarscov
taken
togeth
fact
number
sar
case
epidemiolog
link
wildgam
anim
sarscov
probabl
introduc
human
wild
anim
sold
wet
market
guangdong
china
begin
sar
outbreak
nosocomi
infect
play
import
role
outbreak
first
major
outbreak
hong
kong
occur
princ
wale
hospit
approxim
march
result
sar
case
hospit
worker
end
outbreak
sar
case
hong
kong
involv
worker
hospit
canada
first
larg
outbreak
also
occur
commun
hospit
affect
patient
hospit
staff
major
sourc
transmiss
human
droplet
aerosol
fomit
deposit
droplet
onto
respiratori
epithelium
probabl
initi
infect
whether
infect
occur
oral
conjunctiv
epithelium
remain
unknown
sarscov
detect
tear
asymptomat
infect
human
appear
rare
event
despit
rapid
spread
sar
worldwid
household
transmiss
sar
rel
averag
number
secondari
infect
caus
one
case
low
compar
influenza
superspread
event
infect
individu
disproportion
contribut
transmiss
ie
difficult
intub
intens
care
unit
result
infect
number
hous
staff
characterist
outbreak
factor
associ
superspread
event
well
understood
may
includ
coinfect
virus
host
factor
immunosuppress
andor
environment
factor
number
infect
staff
hospit
strongli
correl
number
admit
sar
patient
length
type
exposur
use
person
protect
equip
glove
mask
later
outbreak
shown
person
protect
equip
significantli
decreas
nosocomi
infect
play
signific
role
outbreak
natur
histori
sarscov
document
sever
studi
initi
symptom
unremark
common
viral
infect
upper
respiratori
tract
day
cough
lowgrad
fever
progress
rapidli
fullblown
pneumonia
requir
hospit
often
includ
mechan
ventil
fever
malais
lymphopenia
elev
liver
enzym
togeth
infiltr
consolid
chest
xray
typic
quantit
polymeras
chain
reaction
pcr
studi
shown
viral
load
high
lower
respiratori
tract
low
upper
respiratori
tract
viral
load
upper
respiratori
tract
fece
low
first
day
peak
approxim
day
mark
contrast
respiratori
viral
infect
influenza
peak
soon
onset
symptom
unusu
featur
sarscov
infect
explain
low
transmiss
earli
ill
perhap
explain
outbreak
countri
limit
case
importantli
explain
poor
sensit
earli
revers
transcriptas
rt
pcr
test
nasopharyng
np
specimen
collect
earli
ill
although
main
clinic
symptom
sever
respiratori
tract
diseas
viru
also
infect
organ
approxim
quarter
sar
patient
wateri
diarrhea
viru
cultur
fece
urin
well
respiratori
viru
also
detect
rtpcr
serum
plasma
peripher
blood
leukocyt
howev
viremia
might
short
live
patient
also
pronounc
peripher
tcell
lymphocytopenia
reduc
cell
count
third
individu
count
less
infect
individu
high
serum
viral
load
poor
prognosi
day
ill
high
viral
load
np
aspir
fece
serum
independ
predictor
advers
clinic
outcom
sarscov
invari
found
lung
individu
die
sar
viral
load
usual
higher
die
earlier
cours
ill
day
approxim
one
quarter
patient
sar
requir
manag
intens
care
unit
overal
case
fatal
rate
diseas
sever
mortal
correl
age
highest
mortal
rate
occur
year
age
lowest
rate
group
children
acquir
sar
seldom
requir
intens
care
mechan
although
sarscov
found
month
fece
infect
individu
evid
viru
persist
resolut
ill
approach
diagnos
specif
viral
infect
delin
understand
natur
histori
infect
natur
histori
viral
infect
indic
appropri
clinic
specimen
diagnosi
ie
viru
secret
detect
cours
diseas
differ
specimen
type
would
expect
posit
viru
sarscov
except
evolut
diagnost
sar
differ
virus
need
facil
viru
isol
difficulti
cultur
viru
infect
individu
late
outbreak
possibl
result
genet
drift
viru
preclud
use
cultur
diagnosi
outbreak
set
furthermor
late
seroconvers
week
infect
patient
elimin
serolog
diagnosi
detect
recent
infect
first
serolog
test
use
sarscovinfect
cell
microscop
slide
immunofluoresc
stain
enzymelink
immunosorb
assay
test
crude
cell
lysat
contain
sarscov
antigen
detect
serum
antibodi
use
togeth
multipl
specimen
viru
isol
serolog
prove
use
identifi
patient
begin
outbreak
howev
prove
less
satisfactori
diagnos
new
case
first
day
onset
symptom
initi
cultur
cov
patient
hong
kong
enabl
earli
identif
sarscov
electron
microscopi
led
develop
first
nucleic
acid
amplif
test
naat
detect
sarscov
rna
identif
cov
electron
microscopi
led
search
conserv
region
cov
genom
develop
rtpcr
assay
sarscov
rna
molecular
diagnost
test
use
naat
quickli
becam
mainstay
sar
diagnosi
first
rtpcr
assay
describ
sarscov
rna
target
polymeras
pol
region
gene
first
pcr
primer
develop
collabor
effort
laboratori
particip
world
health
organ
sar
laboratori
consortium
primer
use
develop
nest
nonnest
onestep
twostep
combin
separ
revers
transcriptas
reaction
convent
heat
block
rtpcr
well
realtim
pcr
assay
tabl
drosten
use
two
set
primer
nest
pcr
format
amplifi
fragment
assay
analyt
sensit
genom
equival
ge
per
reaction
also
use
primer
realtim
taqman
assay
show
realtim
assay
equival
sensit
nest
assay
detect
sarscov
rna
clinic
specimen
studi
report
pcr
result
specimen
obtain
patient
frankfurt
germani
patient
hanoi
vietnam
ksiazek
use
differ
pol
gene
primer
describ
twostep
assay
sensit
ge
use
specimen
six
countri
report
rtpcr
sensit
cultur
diagnos
sar
clear
howev
mani
specimen
test
method
poutanen
also
describ
twostep
pol
assay
detect
sarscov
rna
clinic
specimen
obtain
patient
toronto
sar
outbreak
first
three
assay
use
test
small
number
clinic
specimen
compar
naat
preclud
assess
perform
lau
describ
enhanc
rt
ert
pcr
involv
target
preamplif
use
two
separ
amplif
region
pol
gene
first
pcr
convent
heat
block
assay
follow
taqman
realtim
amplif
use
product
first
reaction
result
product
ertpcr
amplicon
assay
use
test
specimen
patient
hong
kong
china
enhanc
assay
detect
posit
versu
posit
taqman
howev
analyt
sensit
assay
provid
addit
test
discord
specimen
perform
allow
compar
assay
perform
follow
origin
assay
addit
test
develop
amplifi
altern
gene
target
mahoni
introduc
onestep
twostep
realtim
assay
amplifi
fragment
nucleocapsid
nuc
gene
onestep
taqman
assay
sensit
ge
evalu
test
nuc
assay
similar
analyt
sensit
pol
bressler
describ
twostep
realtim
taqman
assay
amplifi
fragment
nuc
gene
analyt
sensit
ge
assay
evalu
analyt
sensit
use
armor
rna
spike
specimen
involv
test
sar
specimen
show
nuc
gene
assay
similar
sensit
pol
assay
drosten
colleagu
also
show
onestep
taqman
assay
target
nuc
gene
detect
similar
number
posit
specimen
compar
two
pol
assay
evalu
assay
test
clinic
specimen
realtim
pcr
assay
introduc
sarscov
use
pol
nuc
gene
target
realtim
assay
offer
increas
turnaround
time
abil
quantit
viral
load
wang
test
sar
specimen
use
twostep
assay
amplifi
fragment
pol
gene
although
test
signific
number
specimen
indic
analyt
clinic
sensit
assay
houng
introduc
twostep
realtim
assay
amplifi
region
region
ncr
genom
assay
excel
analyt
sensit
ge
evalu
sar
specimen
poon
introduc
realtim
multiplex
assay
target
pol
gene
rrna
intern
control
onestep
taqman
assay
analyt
sensit
ge
evalu
use
nasopharyng
specimen
sar
patient
use
intern
control
use
identifi
specimen
contain
amplif
inhibitor
lack
specimen
rna
result
fail
extract
studi
np
specimen
fail
amplifi
intern
control
indic
success
rna
isol
absenc
amplif
two
recent
report
describ
consensu
pol
gene
primer
detect
cov
rna
includ
sarscov
adachi
use
consensu
primer
amplifi
fragment
pol
onestep
assay
analyt
sensit
ge
test
sar
specimen
well
cultur
viru
turkey
infecti
bronchiti
viru
show
consensu
rtpcr
assay
could
detect
four
cov
woo
describ
twostep
convent
heat
block
nonrealtim
assay
use
consensu
pol
primer
amplifi
fragment
pol
gene
assay
use
detect
novel
human
respiratori
cov
nonsar
pneumonia
sar
outbreak
hong
kong
assay
use
consensu
primer
abl
detect
sarscov
although
author
show
assay
abl
isotherm
amplif
format
includ
nucleic
acid
sequencebas
amplif
loopmedi
isotherm
amplif
lamp
also
use
detect
sarscov
rna
thai
use
six
primer
includ
two
outer
two
inner
two
loop
primer
recogn
eight
distinct
region
pol
gene
amplifi
sarscov
rna
use
lamp
onestep
lamp
assay
amplifi
fragment
analyt
sensit
plaqu
form
unit
evalu
assay
test
specimen
vietnames
patient
lamp
convent
rtpcr
lamp
detect
posit
specimen
compar
rtpcr
sensit
specif
discord
analysi
determin
whether
addit
posit
specimen
true
posit
falseposit
perform
nucleic
acid
sequencebas
amplif
test
sarscov
rna
describ
test
yet
evalu
clinic
juang
recent
describ
multiplex
rtpcr
amplifi
two
sarscov
gene
use
gene
chip
detect
platform
first
rtpcr
assay
sar
evalu
perform
time
assay
develop
littl
known
natur
histori
sar
includ
viru
present
variou
bodi
compart
reason
care
must
taken
read
earli
public
especi
word
sensit
sensit
use
earli
public
often
use
word
sensit
context
rate
posit
articl
said
pcr
sensit
np
specimen
first
day
infect
realli
meant
viru
present
np
specimen
assay
may
clinic
sensit
higher
natur
histori
infect
dictat
np
specimen
would
posit
best
time
determin
perform
sensit
specif
test
involv
compar
appropri
gold
standard
refer
standard
determin
sensit
specif
one
rtpcr
assay
test
question
must
compar
best
possibl
refer
standard
defin
true
statu
specimen
one
test
compar
anoth
test
discord
specimen
posit
one
test
neg
anoth
examin
third
test
act
arbitr
determin
true
statu
specimen
way
true
posit
defin
posit
two
test
use
refer
new
assay
develop
evalu
use
three
test
help
determin
perform
individu
test
naat
describ
sar
tabl
evalu
comparison
amplif
test
two
report
tabl
involv
comparison
three
assay
one
studi
use
combin
refer
standard
determin
sensit
specif
specif
test
first
report
drosten
test
sar
specimen
three
differ
test
includ
inhous
rtpcr
two
first
gener
commerci
test
realart
hpa
coronaviru
kit
artu
hamburg
germani
sar
coronaviru
lightcycl
kit
roch
branchburg
nj
indic
sensit
artu
roch
calcul
number
posit
sampl
divid
number
sampl
howev
indic
result
specimen
three
differ
test
use
combin
refer
standard
calcul
perform
second
public
mahoni
colleagu
test
sar
specimen
seven
differ
assay
six
inhous
artu
test
use
combin
standard
posit
two
test
calcul
perform
shown
tabl
base
small
number
posit
specimen
sensit
test
rang
specif
rang
interest
commerci
avail
artu
test
sensit
specif
second
evalu
three
differ
commerci
avail
test
artu
roch
eragen
bioscienc
madison
wi
total
sar
specimen
test
three
commerci
assay
plu
two
inhous
assay
tabl
use
combin
refer
standard
posit
two
assay
posit
neg
sensit
artu
eragen
roch
assay
specif
addit
evalu
involv
multipl
test
larger
number
specimen
requir
determin
true
perform
commerci
assay
poor
clinic
sensit
first
gener
assay
concern
sar
return
direct
manufactur
reformul
assay
mention
natur
histori
sarscov
infect
determin
clinic
specimen
posit
viru
point
cours
infect
np
specimen
often
neg
first
week
infect
highest
posit
rate
second
week
ill
peak
approxim
day
quantit
pcr
reveal
viral
load
highest
lower
tract
specimen
bronchoalveolar
lavag
sputum
endotrach
aspir
bronchoalveolar
lavag
specimen
posit
frequent
np
collect
bronchoalveolar
lavag
specimen
howev
associ
increas
risk
nosocomi
transmiss
risk
health
care
worker
halt
mani
institut
low
viru
detect
rate
np
specimen
earli
cours
infect
underscor
import
optim
time
specimen
type
diagnosi
center
diseas
control
recommend
multipl
specimen
sourc
test
nasopharyng
plu
oropharyng
serumplasma
first
week
ill
nasopharyng
plu
oropharyng
stool
specimen
first
week
ill
interpret
posit
diagnosi
base
pcr
test
gener
recommend
patient
either
two
posit
clinic
specimen
differ
anatom
site
posit
specimen
site
two
separ
occas
replic
sarscov
gastrointestin
tract
confirm
electron
microscopi
rtpcr
test
biopsi
postmortem
specimen
discoveri
sarscov
fece
indic
viru
rapidli
dissemin
np
tissu
suggest
viru
could
transmit
fecal
rout
case
stool
specimen
sarscov
rna
could
detect
high
level
sever
week
even
month
wherea
viru
cultur
posit
first
week
fecal
specimen
high
viral
load
end
first
week
ill
specimen
choic
diagnosi
second
week
diseas
possibl
viru
replic
continu
week
gastrointestin
tract
viru
complex
antibodi
longer
infect
transmiss
consist
epidemiolog
find
sarscov
rna
detect
specimen
includ
blood
cerebrospin
fluid
urin
tear
nonrespiratori
specimen
stool
specimen
shown
highest
posit
rate
highest
viral
load
suggest
fecal
specimen
good
altern
respiratori
tract
specimen
identif
sar
patient
test
serum
plasma
viral
rna
disappoint
first
subsequ
studi
shown
posit
rate
serum
plasma
respect
first
week
second
studi
confirm
result
plasma
posit
rate
first
day
demonstr
sarscov
rna
peripher
leukocyt
may
provid
yet
anoth
altern
specimen
earli
diagnosi
effort
aim
optim
rna
extract
larger
volum
specimen
stool
plasma
rais
sensit
rtpcr
nonrespiratori
specimen
identifi
sar
patient
realtim
pcr
assay
provid
viral
load
may
also
use
identifi
patient
increas
risk
wors
outcom
term
surviv
requir
intens
care
assist
ventil
recent
studi
confirm
high
viral
load
np
specimen
associ
need
intens
care
independ
predictor
mortal
quantit
pcr
assay
may
also
provid
use
prognost
inform
clinic
manag
includ
use
antivir
therapi
approach
increas
sensit
sarscov
rtpcr
test
attempt
vari
degre
success
includ
test
multipl
serial
specimen
test
transcript
well
genom
rna
enhanc
rna
extract
test
multipl
aliquot
specimen
although
yet
evalu
sarscov
proven
use
detect
microorgan
present
low
level
clinic
detect
nucleocapsid
transcript
rtpcr
theori
enhanc
sensit
pcr
diagnosi
subgenom
rna
transcript
contain
nucleocapsid
gene
sequenc
follow
discontinu
transcript
approach
howev
case
rtpcr
assay
target
nuc
gene
sensit
pol
gene
assay
subsequ
studi
shown
viral
rna
clinic
specimen
genom
rna
avail
nuc
rtpcr
assay
howev
provid
confirmatori
assay
posit
specimen
earli
epidem
assist
determin
specif
earli
anoth
approach
improv
sensit
involv
extract
larger
volum
clinic
specimen
use
rna
rtpcr
assay
extract
larger
portion
np
specimen
versu
investig
increas
sensit
rtpcr
specimen
collect
day
diseas
onset
retain
specif
particular
studi
increas
preval
amplif
inhibitor
rna
purif
control
futur
studi
use
amplif
control
pcr
reaction
rule
falseneg
due
pcr
inhibit
commerci
avail
test
recent
appear
includ
realart
hpa
cov
rtpcr
assay
artu
gmbh
genecod
sar
coronaviru
np
pol
multicodertx
kit
eragen
bioscienc
lightcycl
sarscov
kit
roch
diagnost
meaning
evalu
commerci
assay
yet
appear
true
perform
yet
determin
first
gener
assay
appear
suboptim
perform
low
sensit
low
specif
tabl
look
forward
introduct
second
gener
test
improv
sensit
specif
diagnost
compani
also
work
chipbas
assay
detect
sarscov
respiratori
virus
laboratori
polici
well
recommend
center
diseas
control
world
health
organ
posit
test
result
includ
follow
posit
rtpcr
result
repeat
test
use
second
aliquot
origin
specimen
posit
confirm
result
send
specimen
refer
laboratori
test
posit
specimen
second
rtpcr
test
target
differ
part
genom
posit
confirm
refer
laboratori
falseposit
specimen
occur
poorli
design
primer
altern
specimen
collect
low
preval
popul
specif
decreas
preval
infect
decreas
laboratori
test
perform
improperli
neg
rtpcr
test
np
specimen
suspect
sar
patient
rule
sar
sarscov
present
low
level
upper
respiratori
tract
first
week
infect
neg
result
infect
patient
could
due
presenc
pcr
inhibitor
copurifi
rna
poor
qualiti
specimen
specimen
lack
viru
level
viral
rna
np
stool
rise
second
week
ill
followup
np
andor
fecal
specimen
collect
test
pcr
neg
pcr
result
specimen
upper
respiratori
tract
could
trigger
sampl
lower
respiratori
tract
titer
viru
higher
although
collect
invas
specimen
associ
increas
risk
medic
staff
infect
detect
sarscov
plasma
peripher
leukocyt
consid
approach
provid
sensit
first
week
ill
use
multipl
serial
respiratori
tract
fecal
specimen
improv
sensit
pcr
diagnost
test
especi
larger
volum
sampl
extract
larger
proport
sampl
rna
use
first
gener
commerci
avail
pcr
assay
sar
may
suboptim
sensit
use
alon
without
send
parallel
specimen
experienc
refer
laboratori
test
recogn
first
human
infect
caus
zoonot
viru
adapt
new
human
host
mankind
face
continu
possibl
introduct
new
variant
anim
sarsassoci
virus
greater
vigil
requir
make
diagnosi
infect
new
anim
cov
introduc
human
popul
use
rtpcr
assay
use
consensu
primer
sequenc
detect
known
cov
would
recommend
scenario
given
sever
sar
recent
report
laboratoryacquir
appropri
precaut
follow
handl
specimen
submit
sar
investig
test
respiratori
stool
specimen
must
done
use
level
precaut
class
ii
biolog
safeti
cabinet
laboratori
worker
wear
person
protect
equip
includ
longsleev
gown
glove
eye
protect
mask
viru
isol
attempt
routin
clinic
laboratori
sarscov
level
iii
agent
propag
viru
requir
facil
event
sar
return
laboratori
face
signific
challeng
diagnos
sar
common
respiratori
viral
infect
possibl
new
nonconvent
agent
ie
avian
influenza
viru
cocircul
popul
upward
differ
naat
describ
detect
sarscov
rna
clinic
specimen
major
rtpcr
assay
assay
evalu
part
small
number
clinic
specimen
infect
patient
true
perform
characterist
poorli
defin
particularli
case
first
gener
commerci
avail
assay
uniqu
natur
histori
sarscov
infect
dictat
test
respiratori
nonrespiratori
specimen
test
multipl
specimen
patient
send
posit
confirm
refer
laboratori
posit
diagnosi
declar
